Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03), Briefing.com reports. Mersana Therapeutics had a negative net margin of 352.01% and a negative return on equity of 260.65%. The business had revenue of $2.30 million for the quarter, compared to analyst estimates of $8.72 million. During the same quarter in the prior year, the business earned ($0.47) earnings per share. The firm’s revenue was down 78.3% on a year-over-year basis.
Mersana Therapeutics Stock Performance
MRSN stock traded down $0.18 during trading on Friday, reaching $1.31. 1,561,727 shares of the company’s stock were exchanged, compared to its average volume of 1,858,557. Mersana Therapeutics has a 1-year low of $1.07 and a 1-year high of $6.28. The firm has a market cap of $160.29 million, a PE ratio of -1.15 and a beta of 1.55. The company’s fifty day moving average price is $1.91 and its 200-day moving average price is $3.10. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.72.
Wall Street Analyst Weigh In
MRSN has been the topic of several recent analyst reports. Robert W. Baird cut their price target on shares of Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a report on Wednesday. Lifesci Capital upgraded shares of Mersana Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $6.00.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
Further Reading
- Five stocks we like better than Mersana Therapeutics
- 3 Tickers Leading a Meme Stock Revival
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- MarketBeat Week in Review – 8/12 – 8/16
- What Do S&P 500 Stocks Tell Investors About the Market?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.